Management of antithrombotic therapy in patients undergoing regional anesthesia
Abstract
Th e use of antithrombotic drugs increases the risk for the perioperative complications with regional anesthesia. Th e spinal epidural haematoma is a rare but devastating complication which can leave long term consequences. It is necessary to evaluate the risk and benefi t of the regional anesthesia with every patient individually. To avoid the risk we have to strictly follow the antihrombotic therapy indication and dosages of antithrombotic drugs. Also the guidelines on administrating the last dosage of the antithrombotic drug before and its fi rst dosage aft er the scheduled surgery have to be followed. In the article the updated Slovenian guidelines are presented.Downloads
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.